74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Galapagos NV
Open
SectorHealthcare
23.32 4.48
Overview
Share price change
24h
Min
22.32
Max
23.36
Income | 76M 25M |
|---|---|
Sales | 16M 75M |
P/E Sector Avg | 53.92 57.333 |
EPS | 0.287 |
Profit margin | 33.521 |
Employees | 704 |
EBITDA | -52M -48M |
Recommendations | Sell |
|---|---|
12 Months Forecast | -3.96% downside |
Next Earnings | 23 Jul 2025 |
|---|
Market Cap | -7.9M 1.5B |
|---|---|
Previous open | 18.84 |
Previous close | 23.32 |
Galapagos NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Galapagos NV Forecast
Price Target
By TipRanks
-3.96% downside
12 Months Forecast
Average 21.57 EUR -3.96%
High 22 EUR
Low 20.705 EUR
Based on 3 Wall Street analysts offering 12 month price targets forGalapagos NV - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
